successfully verified that serum exosomal miR-25-3p can be used as a noninvasive blood-based biomarker for tumor monitoring in OS patients (55), meanwhile, a study in 2021 (56) confirmed that the plasma exosome-derived sentrin SUMO-specific protease1 (SENP1) was better than plasma SENP1 as a prognostic biomarker in OS. Here, SUMO1 is linked to neoplasm.